Get started
Author

Helen E.J. Tyrrell

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
2010 · P Emery, A Deodhar, et al. · Annals of the Rheumatic Diseases · 348
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
2010 · P P Tak, W F Rigby, et al. · Annals of the Rheumatic Diseases · 307
PDF
Combatting Mucosal Melanoma: Recent Advances and Future Perspectives
2018 · Helen Tyrrell, Miranda Payne · Melanoma Management · 121
Retrospective audit of 957 consecutive 18F-FDG PET–CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma
2018 · Ruth E. Macpherson, Sarah Pratap, et al. · Clinical Sarcoma Research · 115
PDF
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
2021 · Silvio Danese, Jean-Frederic Colombel, et al. · ˜The œLancet. Gastroenterology & hepatology · 98
PDF
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
2020 · William J. Sandborn, Severine Vermeire, et al. · Advances in Therapy · 92
PDF
Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study
2012 · EDWARD C. KEYSTONE, STANLEY B. COHEN, et al. · The Journal of Rheumatology · 71
PDF
Adiponectin Receptor Signaling on Dendritic Cells Blunts Antitumor Immunity
2014 · Peng H. Tan, Helen E.J. Tyrrell, et al. · Cancer Research · 59
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis
2011 · P. Emery, P. J. Mease, et al. · Lara D. Veeken · 54
Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis: Results from the dose-ranging assessment international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) study
2005 · Ronald van Vollenhoven, Joy Schechtman, et al. · Arthritis & Rheumatism · 16
Changing Practice Evaluation—Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols—Experience From a Supraregional Center
2017 · Helen E.J. Tyrrell, David N. Church, et al. · Clinical Genitourinary Cancer · 9
Concurrent Oral 1 - Rheumatoid Arthritis: Treatment [OP4-OP9]: OP4. Inhibition of Radiographic Progression and Improvements in Physical Function at 2 Years, with Increasing Clinical Efficacy Over Time, in Rheumatoid Arthritis (Ra) Patients Treated with Tocilizumab (Tcz): The Lithe Study
2010 · R. Fleischmann, R. Burgos-Vargas, et al. · Lara D. Veeken · 7
OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study
2017 · L. Peyrin-Biroulet, B.G. Feagan, et al. · Journal of Crohn s and Colitis · 6
Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers
2021 · Wenhui Zhang, Helen Tyrrell, et al. · Advances in Therapy · 4
PDF
20 Etrolizumab Improved Endoscopic Score, Patient-reported Outcomes, and Inflammatory Biomarkers in Patients With Moderate to Severe Uc Who Had Failed Tnf Antagonist Therapy: the Hickory Open-label Induction (oli) Cohort
2018 · Laurent Peyrin-Biroulet, David T. Rubin, et al. · Gastroenterology · 4
Etrolizumab Treatment Leads to Early Improvement in Symptoms and Inflammatory Biomarkers in Anti-TNF-refractory Patients in the Open-Label Induction Cohort of the Phase 3 Hickory Study
2017 · Laurent Peyrin-Biroulet, Brian G. Feagan, et al. · Gastroenterology · 4
Tu2006 - Etrolizumab Induction Therapy Improves Histologic Outcomes in Anti-TNF-Failed Patients with Ulcerative Colitis: Results from the Hickory Open-Label Induction Cohort
2018 · David T. Rubin, Brian G. Feagan, et al. · Gastroenterology · 3
A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies
2018 · S. Blagden, P. Spiliopoulou, et al. · Annals of Oncology · 2
Prognostic markers for colorectal cancer
2018 · Helen E.J. Tyrrell, David Kerr · Oncotarget · 2
PDF
PWE-071 Etrolizumab induction in moderate/severe anti-TNF intolerant/refractory (IR) UC: the hickory open-label induction (OLI) trial
2018 · Bu’hussain Hayee, David Rubin, et al. · 2
Rheumatoid Arthritis: Treatment [151-201]: 151. Should we be Looking More Carefully for Methotrexate Induced Liver Disease?
2010 · M. Lloyd, R. Makadsi, et al. · Lara D. Veeken · 2
An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers
2021 · Helen Tyrrell, Renato Ravanello, et al. · Advances in Therapy · 1
PDF
AB0526 Sustained efficacy responses and a consistent safety profile with rituximab repeat treatment over 5 years in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors in the reflex study
2012 · E. Keystone, S.B. Cohen, et al. · Annals of the Rheumatic Diseases · 1
253P Defining fibroblast niches in rectal cancer
2025 · H.E.J. Tyrrell, L. Campo, et al. · Annals of Oncology
PDF
Data from Adiponectin Receptor Signaling on Dendritic Cells Blunts Antitumor Immunity
2023 · Peng H. Tan, Helen E.J. Tyrrell, et al.
Works count: 60
Citation count: 1,330
H-index: 10
I10-index: 10
Year
Topic
Type